Li J - Search Results

1

Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.

Jin Z, Xiang R, Qing K, Li D, Liu Z, Li X, Zhu H, Zhang Y, Wang L, Xue K, Liu H, Xu Z, Wang Y, Li J. Jin Z, et al. Among authors: li d, li j, li x. Cell Oncol (Dordr). 2023 Aug;46(4):1143-1157. doi: 10.1007/s13402-023-00833-6. Epub 2023 May 23. Cell Oncol (Dordr). 2023. PMID: 37219767

2

The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment.

Xia ZG, Xu ZZ, Zhao WL, Zhao SQ, Ding F, Chen Y, Chen QS, Zheng Y, Zhu Q, Hu JP, Shen ZX, Li JM. Xia ZG, et al. Ann Hematol. 2010 Feb;89(2):171-7. doi: 10.1007/s00277-009-0799-2. Epub 2009 Aug 11. Ann Hematol. 2010. PMID: 19669764

3

Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006.

Wang AH, Wang YY, Yao Y, Xu ZZ, Zhou L, Wang L, Zhang L, Chen Y, Shen ZX, Hu J, Li JM. Wang AH, et al. Among authors: li jm. J Exp Clin Cancer Res. 2010 Mar 3;29(1):20. doi: 10.1186/1756-9966-29-20. J Exp Clin Cancer Res. 2010. PMID: 20199658 Free PMC article.

4

[Research progress on second-hit in malignant lymphomagenesis-- review].

Li XY, Li JM. Li XY, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Dec;18(6):1627-31. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010. PMID: 21176385 Review. Chinese.

5

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.

Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z. Li X, et al. Among authors: li j. Ann Hematol. 2012 Jun;91(6):837-45. doi: 10.1007/s00277-011-1375-0. Epub 2011 Dec 9. Ann Hematol. 2012. PMID: 22160255

6

Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.

Li X, Shen W, Cao J, Wang J, Chen F, Wang C, Zou S, Shen B, Zhao R, Li J, Shen Z. Li X, et al. Among authors: li j. Ann Hematol. 2012 Nov;91(11):1721-9. doi: 10.1007/s00277-012-1507-1. Epub 2012 Jun 26. Ann Hematol. 2012. PMID: 22733613

7

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.

Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM. Xu ZZ, et al. Ann Hematol. 2013 Oct;92(10):1351-8. doi: 10.1007/s00277-013-1770-9. Epub 2013 May 2. Ann Hematol. 2013. PMID: 23636313

8

Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.

Xu ZZ, Wang WF, Fu WB, Wang AH, Liu ZY, Chen LY, Guo P, Li JM. Xu ZZ, et al. Leuk Lymphoma. 2014 May;55(5):1151-7. doi: 10.3109/10428194.2013.823492. Epub 2013 Aug 28. Leuk Lymphoma. 2014. PMID: 23841505

9

[Prognostic significance of 18F-FDG PET/CT in aggressive non- Hodgkin's lymphoma: a 10-year retrospective study on 105 cases].

Guo N, Li XY, Zhu HM, Li JM. Guo N, et al. Zhonghua Xue Ye Xue Za Zhi. 2013 Aug;34(8):722-4. doi: 10.3760/cma.j.issn.0253-2727.2013.08.018. Zhonghua Xue Ye Xue Za Zhi. 2013. PMID: 23978029 Chinese. No abstract available.

10

Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.

Li J, Zhu H, Hu J, Mi J, Chen S, Chen Z, Wang Z. Li J, et al. Int J Hematol. 2014 Jul;100(1):38-50. doi: 10.1007/s12185-014-1603-1. Epub 2014 Jun 18. Int J Hematol. 2014. PMID: 24938378 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

193,377 results

Search Page

Filters